Literature DB >> 36127399

Fbxo45 promotes the malignant development of esophageal squamous cell carcinoma by targeting GGNBP2 for ubiquitination and degradation.

Qi Wang1,2, Linhui Wu3, Ruoxue Cao3, Jing Gao1,2, Damin Chai1,2, Yanzi Qin1,2, Li Ma1,2, Shiwu Wu1,2, Yisheng Tao4,5, Jia Ma6, Zhi-Wei Wang7,8.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common and deadly cancers. Fbxo45, a substrate recognition subunit of E3 ligase, is critically involved in tumorigenesis and tumor progression. However, the function of Fbxo45 and the underlying mechanisms have not been elucidated in ESCC. We used cellular and molecular methods to explore the molecular basis of Fbxo45-mediated ESCC development. We found that ectopic overexpression of Fbxo45 promoted the growth of Kyse-150, Kyse30 and ECA-109 cells and inhibited the apoptosis. Moreover, overexpression of Fbxo45 promoted the migration and invasion of ESCC cells. Consistently, knockdown of Fbxo45 exhibited the opposite effects on ESCC cells. Mechanistically, we observed that Fbxo45 binds to GGNBP2 via its SPRY domain and targets GGNBP2 for ubiquitination and degradation. GGNBP2 overexpression exhibited anticancer activity in ESCC cells. Furthermore, Fbxo45 exerted its functions by regulating GGNBP2 stability in ESCC cells. Notably, overexpression of Fbxo45 facilitated tumor growth in mice. Strikingly, Fbxo45 was highly expressed in ESCC tissues, and GGNBP2 had a lower expression in ESCC specimens. High expression of Fbxo45 and low expression of GGNBP2 were associated with poor prognosis in ESCC patients. Fbxo45 was negatively correlated with GGNBP2 expression in ESCC tissues. Therefore, Fbxo45 serves as an oncoprotein to promote ESCC tumorigenesis by targeting the stability of the tumor suppressor GGNBP2 in ESCC.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36127399     DOI: 10.1038/s41388-022-02468-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  46 in total

1.  Geographical distribution and racial disparity in esophageal cancer.

Authors:  Allan Pickens; Mark B Orringer
Journal:  Ann Thorac Surg       Date:  2003-10       Impact factor: 4.330

Review 2.  Ubiquitin and membrane protein turnover: from cradle to grave.

Authors:  Jason A MacGurn; Pi-Chiang Hsu; Scott D Emr
Journal:  Annu Rev Biochem       Date:  2012-03-08       Impact factor: 23.643

Review 3.  Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli.

Authors:  Min Gao; Michael Karin
Journal:  Mol Cell       Date:  2005-09-02       Impact factor: 17.970

Review 4.  Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting.

Authors:  Aaron Ciechanover
Journal:  Best Pract Res Clin Haematol       Date:  2017-09-22       Impact factor: 3.020

Review 5.  Recent advances in SCF ubiquitin ligase complex: Clinical implications.

Authors:  Nana Zheng; Quansheng Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2016-05-05

6.  Global trends in esophageal cancer.

Authors:  Gautam K Malhotra; Ujwal Yanala; Advaitaa Ravipati; Matthew Follet; M Vijayakumar; Chandrakanth Are
Journal:  J Surg Oncol       Date:  2017-03-20       Impact factor: 3.454

Review 7.  Regulation of F-box proteins by noncoding RNAs in human cancers.

Authors:  Min Lin; Yichi Xu; Ying Gao; Chunyu Pan; Xueqiong Zhu; Zhi-Wei Wang
Journal:  Cancer Lett       Date:  2019-09-20       Impact factor: 8.679

Review 8.  Roles of F-box proteins in cancer.

Authors:  Zhiwei Wang; Pengda Liu; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

Review 9.  Oesophageal carcinoma.

Authors:  Arjun Pennathur; Michael K Gibson; Blair A Jobe; James D Luketich
Journal:  Lancet       Date:  2013-02-02       Impact factor: 79.321

Review 10.  Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer.

Authors:  Dan D Hershko
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.